By Benjamin Chiou
Date: Tuesday 16 Dec 2025
(Sharecast News) - American pharmaceutical giant Pfizer expects revenues and profits to slip slightly in 2026, partly as a result of lost revenues from its Covid-19 products.
| Patent Woes Threaten Drug Firms | 07-Mar-2011 | New York Times |
| Stocks push higher on deals and strong earnings | 09-Feb-2011 | USA Today |
| Dow soars to close above 12,000 | 02-Feb-2011 | Wall Street Journal |
| Pfizer To Close UK Plant And Axe 2,400 Jobs | 01-Feb-2011 | Sky News |
| Despite good earnings reports, stocks tumble | 21-Oct-2009 | Wall Street Journal |
| Currency | US Dollars |
| Share Price | $ 25.18 |
| Closing Price Change | $ 0.28 |
| % Change | 0.00 % |
| 52 Week High | $27.37 |
| 52 Week Low | $21.59 |
| Volume | 0 |
| Shares Issued | 5,667m |
| Beta | 0.53 |
| RiskGrade | 102 |
| Strong Buy | 4 |
| Buy | 6 |
| Neutral | 16 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

You are here: research